Royal Society GlaxoSmithKline Prize and Lecture
This prize lecture is made for original contributions to medical and veterinary sciences.
Sir Paul Nurse FRS was awarded the Royal Society GlaxoSmithKline Prize and Lecture in 1992.
The Royal Society GlaxoSmithKline Prize and Lecture is awarded biennially for 'original contributions to medical and veterinary sciences published within ten years from the date of the award'. There is no restriction on the nationality of the recipient.
The award was initially established following a donation from The Wellcome Foundation. Since 2002 it has been supported by GlaxoSmithKline Limited. The first award was made in 1980.
The medal is of gold and is accompanied by a gift of £2,500. The award is normally made to one individual and the winner is called upon to deliver a lecture at the Society.
The next call for nominations opens on 28 November 2014.
The recipient is chosen by the Council of the Royal Society on the recommendation of the Biological Sciences Award Committee. Nominations are valid for five years after which the candidate cannot be re-nominated until a year after the nomination has expired. Employees of GlaxoSmithKline are not eligible for the award.
Most recent medallist
Dr Nicholas Lydon FRS was awarded the 2014 Royal Society GlaxoSmithKline Prize and Lecture for the development of the drug imatinib, a targeted tyrosine kinase inhibitor that has transformed the treatment of chronic myelogenous leukaemia (CML) and is a paradigm for cancer drug discovery.